TY - JOUR
T1 - Hyperbiofilm phenotype of Pseudomonas aeruginosa defective for the PlcB and PlcN secreted phospholipases
AU - Lewenza, Shawn
AU - Charron-Mazenod, Laetitia
AU - Afroj, Shirin
AU - Van Tilburg Bernardes, Erik
N1 - Funding Information:
The authors thank Steve Shideler, Mike Wilton, and Tao Dong’s lab for technical support with protein purification. This research was supported by a Natural Sciences and Engineering Research Council (NSERC) Discovery Grant. EVTB was supported by the Beverly Phillips Rising Star and Cystic Fibrosis Canada Studentships.
Publisher Copyright:
© 2017, Canadian Science Publishing. All rights reserved.
PY - 2017
Y1 - 2017
N2 - Biofilms are dense communities of bacteria enmeshed in a protective extracellular matrix composed mainly of exopolysaccharides, extracellular DNA, proteins, and outer membrane vesicles (OMVs). Given the role of biofilms in antibiotic-tolerant and chronic infections, novel strategies are needed to block, disperse, or degrade biofilms. Enzymes that degrade the biofilm matrix are a promising new therapy. We screened mutants in many of the enzymes secreted by the type II secretion system (T2SS) and determined that the T2SS, and specifically phospholipases, play a role in biofilm formation. Mutations in the xcp secretion system and in the plcB and plcN phospholipases all resulted in hyperbiofilm phenotypes. PlcB has activity against many phospholipids, including the common bacterial membrane lipid phosphatidylethanolamine, and may degrade cell membrane debris or OMVs in the biofilm matrix. Exogenous phospholipase was shown to reduce aggregation and biofilm formation, suggesting its potential role as a novel enzymatic treatment to dissolve biofilms.
AB - Biofilms are dense communities of bacteria enmeshed in a protective extracellular matrix composed mainly of exopolysaccharides, extracellular DNA, proteins, and outer membrane vesicles (OMVs). Given the role of biofilms in antibiotic-tolerant and chronic infections, novel strategies are needed to block, disperse, or degrade biofilms. Enzymes that degrade the biofilm matrix are a promising new therapy. We screened mutants in many of the enzymes secreted by the type II secretion system (T2SS) and determined that the T2SS, and specifically phospholipases, play a role in biofilm formation. Mutations in the xcp secretion system and in the plcB and plcN phospholipases all resulted in hyperbiofilm phenotypes. PlcB has activity against many phospholipids, including the common bacterial membrane lipid phosphatidylethanolamine, and may degrade cell membrane debris or OMVs in the biofilm matrix. Exogenous phospholipase was shown to reduce aggregation and biofilm formation, suggesting its potential role as a novel enzymatic treatment to dissolve biofilms.
KW - Biofilm formation
KW - Hyperbiofilm
KW - Matrix
KW - Phospholipase
KW - PlcB
KW - PlcN
KW - Pseudomonas aeruginosa
UR - http://www.scopus.com/inward/record.url?scp=85037038852&partnerID=8YFLogxK
U2 - 10.1139/cjm-2017-0244
DO - 10.1139/cjm-2017-0244
M3 - Journal Article
C2 - 28609638
AN - SCOPUS:85037038852
SN - 0008-4166
VL - 63
SP - 780
EP - 787
JO - Canadian Journal of Microbiology
JF - Canadian Journal of Microbiology
IS - 9
ER -